XML 274 R217.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment information - Schedule of Reconciliation Between Business Operating Income for the Segments and Income Before Tax and Investments Accounted for Using the Equity Method (Details)
€ in Millions, $ in Millions
 1 Months Ended 12 Months Ended
Nov. 30, 2022
EUR (€)
Nov. 30, 2022
USD ($)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2022
EUR (€)
Disclosure of operating segments [line items]          
Net income attributable to non-controlling interests     € 58 € 36 [1],[2] € 113 [1],[2]
Fair value remeasurement of contingent consideration     (96) (93) [2] 27 [2]
Restructuring costs and similar items     (1,396) (1,030) [2],[3] (1,077) [2],[3]
Other gains and losses, and litigation     (470) (196) [2] (143) [2]
Operating income     7,252 6,960 [2],[4] 10,162 [2],[4],[5]
Financial expenses     (1,073) (1,293) [2],[4],[6] (430) [2],[4],[5],[6]
Financial income     519 584 [2],[4],[6] 205 [2],[4],[5],[6]
Income before tax and investments accounted for using the equity method     6,698 6,251 [2],[4],[7] 9,937 [2],[4],[5],[7]
Immuno-oncology collaboration agreement | Regeneron Pharmaceuticals, INC          
Disclosure of operating segments [line items]          
Regular milestone payments for projects under collaboration agreements € 96 $ 100      
Other intangible assets          
Disclosure of operating segments [line items]          
Impairment of other intangible assets, net of reversals (excluding software)     265 932 (454)
Other intangible assets | NK Cell and ProXTen technology platforms          
Disclosure of operating segments [line items]          
Impairment of other intangible assets, net of reversals (excluding software)       833  
Other intangible assets | SAR444245          
Disclosure of operating segments [line items]          
Impairment of other intangible assets, net of reversals (excluding software)         1,586
Eloctate [Member]          
Disclosure of operating segments [line items]          
Reversal amount         2,154
Eloctate [Member] | Research and development projects and technology platforms          
Disclosure of operating segments [line items]          
Reversal amount         600
Impairment of other intangible assets, net of reversals (excluding software)         600
Biopharma (operating segment)          
Disclosure of operating segments [line items]          
Impairment of other intangible assets, net of reversals (excluding software)     415    
Biopharma (operating segment) | Other intangible assets          
Disclosure of operating segments [line items]          
Impairment of other intangible assets, net of reversals (excluding software)     225    
Biopharma (operating segment) | Research and development projects and technology platforms          
Disclosure of operating segments [line items]          
Impairment of other intangible assets, net of reversals (excluding software)     640    
Biopharma (operating segment) | Clinical Study          
Disclosure of operating segments [line items]          
Impairment of other intangible assets, net of reversals (excluding software)     239    
Operating segments          
Disclosure of operating segments [line items]          
Business operating income     11,343 11,178 [4] 12,793 [4],[5]
Material reconciling items          
Disclosure of operating segments [line items]          
Share of profit/(loss) from investments accounted for using the equity method [8]     (136) (101) [4] (76) [4],[5]
Net income attributable to non-controlling interests [9]     14 18 [4] 16 [4],[5]
Amortization and impairment of intangible assets [10]     (1,997) (2,807) [4] (1,375) [4],[5]
Fair value remeasurement of contingent consideration     (96) (93) [4] 27 [4],[5]
Expenses arising from the impact of acquisitions on inventories [11]     (10) (9) [4] (3) [4],[5]
Restructuring costs and similar items [12]     (1,396) (1,030) [4] (1,077) [4],[5]
Other gains and losses, and litigation [13]     € (470) € (196) [4] € (143) [4],[5]
[1] Cash flows of the Opella business are presented separately in accordance with IFRS 5 (Non-Current Assets Held for Sale and Discontinued Operations).
[2] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[3] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[4] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[5] 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo transaction (€706 million net of tax)
[6] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[7] (a) Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[8] (b)Joint ventures and associates with which Sanofi has entered into a strategic alliance.
[9] (c)Excludes (i) restructuring costs and (ii) other adjustments attributable to non-controlling interests.
[10] (d)For 2024, this line includes a net impairment charge of €248 million mainly due to a recognition of impairment losses of €640 million against on various
research and development projects – including a €239 million loss resulting from the decision taken in February 2025 to discontinue a phase 3 clinical
study investigating of a vaccine candidate to prevent invasive E.coli disease - partially offset by impairment losses reversals, recognized in connection
with the disposals of the ProXTen platform and Enjaymo, for €225 million and €167 million respectively. For 2023, this amount mainly comprises an
impairment loss of €833 million, reflecting the impact of the strategic decision to de-prioritize certain R&D programs, in particular those related to the
NK Cell and ProXTen technology platforms. For 2022, this line includes a reversal of €2,154 million on Eloctate franchise products following FDA
approval of ALTUVIIIO on February 22, 2023, partially offset by an impairment loss of €1,586 million on intangible assets relating to SAR444245 (non-
alpha interleukin-2).
[11] (e)This line records the impact of the workdown of acquired inventories remeasured at fair value at the acquisition date.
[12] (f) See note D.27
[13] (g)See note D.28.